Nucleai and Sirona Dx Form Strategic Partnership to Advance Spatial Proteomics in Drug Development
核心洞察
Nucleai (搜索) and Sirona Dx (搜索) announced a strategic partnership to deliver a fully integrated spatial proteomics (搜索) solution for pharmaceutical and biotechnology companies.
The collaboration addresses the significant gap between spatial proteomics (搜索) data generation and actionable biological insights, with critical biomarker information often remaining under-extracted.
The integrated offering combines Sirona Dx (搜索)'s assay development expertise with Nucleai (搜索)'s AI-powered spatial analytics to support applications across oncology (搜索), immunology (搜索), and neuroscience (搜索).
Nucleai (搜索), a leader in AI-powered spatial biology analytics, and Sirona Dx (搜索), a technical contract research organization specializing in spatial biology and single-cell services, have announced a strategic partnership to deliver a fully integrated and scalable spatial proteomics (搜索) solution for pharmaceutical and biotechnology companies. The collaboration addresses a critical gap in the industry where substantial biological value from spatial proteomics data remains unrealized.
Addressing Critical Data Translation Challenges
Spatial proteomics (搜索) platforms are generating increasingly rich and complex tissue data, yet a significant portion of that data's biological value remains unrealized. Critical insights, including novel spatial biomarkers (搜索), treatment response signatures, and patient stratification patterns, are often under-extracted due to sub-optimal assay development and fragmentation across assay development, imaging, and analytics. As multiplex imaging technologies advance, the gap between data generation and actionable insight continues to widen, leaving substantial value unrealized.
Integrated End-to-End Solution
The partnership introduces a premium, fully integrated offering for pharma sponsors, delivered as a single engagement unified across the entire workflow. Sirona Dx (搜索) leads assay design, development, and validation to ensure high-quality image generation, while Nucleai (搜索) delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Together, the companies provide a seamless end-to-end solution in which highest quality tissue data is connected directly to actionable biological insight.
"Until now, pharma teams haven't had a seamless way to translate spatial proteomics (搜索) data into actionable biological insight," said Avi Veidman, CEO of Nucleai (搜索). "Together with Sirona Dx (搜索), we're delivering a single, integrated path from tissue data to meaningful biological insight — enabling more confident biomarker decisions and ultimately improving the probability of clinical success."
Broad Therapeutic Applications
The joint offering supports applications across oncology (搜索), immunology (搜索), and neuroscience (搜索), including biomarker discovery and validation, patient stratification, mechanism of action studies, and clinical trial biomarker programs. This comprehensive approach addresses the growing demand from pharmaceutical sponsors for integrated spatial biology solutions that can match both the quality and complexity of their data.
"Pharma sponsors are investing heavily in spatial biology and need solutions that match both the quality and complexity of their data," said Nasry Yassa, CEO of Sirona Dx (搜索). "Our partnership with Nucleai (搜索) augments our capabilities to deliver fully integrated insight, providing a more seamless and effective model for supporting drug development programs."
Industry Impact and Timing
The partnership, combining best-in-class experimental and analytical capabilities, is strategically timed to meet growing demand from pharma sponsors for integrated spatial biology solutions. Sirona Dx (搜索) operates a GCLP- and CLIA-accredited laboratory with active Phase I and Phase II spatial biology studies, enabling deeper biological understanding and more informed clinical decision-making.
The collaboration represents a significant step forward in addressing the fragmentation that has historically limited the translation of spatial proteomics (搜索) data into actionable insights for drug development programs across multiple therapeutic areas.